Financials data is unavailable for this security.
View more
Year on year Chiome Bioscience Inc grew revenues 8.19% from 630.82m to 682.46m while net income improved from a loss of 1.24bn to a smaller loss of 1.22bn.
Gross margin | 55.28% |
---|---|
Net profit margin | -190.76% |
Operating margin | -191.46% |
Return on assets | -69.09% |
---|---|
Return on equity | -101.15% |
Return on investment | -96.39% |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at Chiome Bioscience Inc fell by 401.72m. Cash Flow from Financing totalled 667.30m or 97.78% of revenues. In addition the company used 1.07bn for operations while cash from investing totalled 173.00k.
Cash flow per share | -21.14 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 18.99 |
---|---|
Tangible book value per share | 18.99 |
More ▼
Balance sheet in JPYView more
Current ratio | 3.29 |
---|---|
Quick ratio | 3.17 |
Total debt/total equity | 0.2729 |
---|---|
Total debt/total capital | 0.2144 |
More ▼